High Prevalence of Dementia and R&D of New Drugs to Augment Growth of Dementia Drugs Market

 

Dementia Drugs Market

Dementia is one of the most common age-related medical conditions. As we age, mental processes and memory become affected by changes in the brain, resulting in problems with memory, attention, mood, and behavior. Dementia can occur in anyone, although it is more common in elderly adults and people suffering from other mental disorders such as depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, and post-traumatic stress disorder.

Market Dynamics

High prevalence of dementia is expected to propel growth of the dementia drugs market. For instance, according to Alzheimer’s Association, around 5.8 million people in the U.S. aged 65 and older are living with Alzheimer's dementia in 2020. Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.         

R&D of new drugs is expected to offer lucrative growth opportunities for players in the dementia drugs market. For instance, in September 2020, researchers from Garvan Institute of Medical Research in New South Wales, Australia, reported that metformin, a common type 2 diabetes drug, may be effective in reducing the risk of dementia in individuals with type 2 diabetes.

Among regions, North America is expected to witness significant growth in the dementia drugs market, owing to R&D of new drugs in the region. For instance, in December 2020, Prevail Therapeutics Inc., a biotechnology company announced that the first patient has been dosed in the Phase 1/2 PROCLAIM clinical trial evaluating PR006, an investigational AAV9 gene therapy delivering the GRN gene, for the treatment of frontotemporal dementia patients with GRN mutations.

Competitive Analysis

Major players operating in the dementia drugs market include, Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., BioXcel Therapeutics, Inc., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc.., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.

Major players operating in the dementia drugs market are focused on R&D to expand their product portfolio. For instance, in January 2021, BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that BXCL501, the company’s proprietary, orally dissolving thin film formulation of dexmedetomidine, met the primary and secondary endpoints of the TRANQUILITY trial at the 60 mcg dose level for the treatment of agitation in dementia.


Comments

Post a Comment

Popular posts from this blog

Increasing Consumption and Production of Fertilizers to Upsurge the Growth of the Agrochemicals Market

Image
  Agrochemical products are those chemicals that are used to increase the production of an agricultural environment. Agrochemical chemicals typically include pesticides, fertilizers, lime precursors, acidizing and alkalizing agents (all of which are designed to alter the normal pH level of the soil), lime stabilizers, and other nutrients that are required for plant growth. These chemicals are widely used by farmers and are crucial to the functioning of modern agriculture. The use of these chemicals presents a number of concerns both from the perspective of the environment and the human body. The increasing need for improving crop production due to the growing concern of food security and lack of arable land is fueling the growth of agrochemicals market . Growing advancement in technology is raising adoption of advanced and sustainable farming practices which is again propelling the growth of the market. The increasing population coupled with the growing usage of fertilizers around th
Read more

High Prevalence of Cancer and R&D in Anti-Cd39 Antibodies to Augment Growth of Anti-body Coupled T Receptor Therapy Market

Image
  Antibody-Coupled T cell Receptor (ACTR) is an autologous engineered T cell therapy that combines the Fc receptor, CD16, with endogenous T cell signaling and costimulatory domains. It is combined with tumor-targeting antibodies to exert potent anti-tumor immune responses and eliminate cancerous cells. ACRT has demonstrated potential in the treatment of multiple myeloma and HER2+ advanced cancers. Market Dynamics R&D in anti-CD39 antibodies is expected to propel growth of the Anti-body Coupled T Receptor Therapy Market . For instance, in December 2020, Arcus Biosciences, Inc. expanded its existing partnership with WuXi Biologics, a developer of biologics technology platforms, for R&D in anti-CD39 antibodies using WuXi Bio’s proprietary technology. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 canc
Read more

Increasing Prevalence of Muscular Dystrophy to Augment the Muscular Dystrophy Treatment Market Growth

Image
  Muscular dystrophy is a common disease that causes muscles to become weaker and unable to continue to develop properly. Because it often affects young children as well as adults, it can be difficult to detect. However, once symptoms are noticed, steps must be taken to prevent the disease. There are many treatment options available for muscular dystrophy. The severity of the disease will determine what type of treatment is best for your situation. Muscular dystrophy treatment involves breathing aids, therapy, surgery, or medication, which may help maintain function, but life span is often shortened. Market Dynamics: Increasing prevalence or incidence of muscular dystrophy, especially in the North America, is expected to propel the growth of the muscular dystrophy treatment market . For instance, one in 3,500 male babies born worldwide are affected with Duchenne muscular dystrophy (DMD), according to the National Organization for Rare Disorders. Moreover, in 2019, around 349 new ca
Read more